CD8A and urinary bladder cancer: Finally, to further validate the value of our CD8+ T cell-related prognostic model in predicting the immunotherapy response, we analyzed RNA-seq data of pretreatment samples of 298 bladder cancer patients from the IMvigor210 cohort before anti-PD-L1 treatment.